Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Innovative Pharmaceutical Biotech ( (HK:0399) ).
Starcoin Group Limited has announced a change to its principal place of business and contact details in Hong Kong, effective 19 January 2026. The company has relocated its main Hong Kong office to the 21st Floor of the Henley Building at 5 Queen’s Road Central in Central, Hong Kong, and has updated its telephone contact while keeping its facsimile number unchanged, a procedural move that signals an administrative shift in its local operations but does not indicate any change in corporate strategy or business direction for shareholders and stakeholders.
The most recent analyst rating on (HK:0399) stock is a Sell with a HK$0.10 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.
More about Innovative Pharmaceutical Biotech
Starcoin Group Limited, formerly known as Innovative Pharmaceutical Biotech Limited, is a Hong Kong-listed company incorporated in the Cayman Islands and continued in Bermuda with limited liability, trading under stock code 399. The group operates through a board comprising executive, non-executive and independent non-executive directors, reflecting a typical diversified governance structure for a listed entity, though the announcement does not detail its specific business segments or products.
Average Trading Volume: 20,309,992
Technical Sentiment Signal: Sell
Current Market Cap: HK$220.7M
For a thorough assessment of 0399 stock, go to TipRanks’ Stock Analysis page.